LABT
No price yet
Announcements
Nothing here yet
Daily updates
- Lakewood-Amedex reported encouraging preclinical Bisphosphocin data, with Nu-8 achieving up to 97% E. coli suppression in a rodent UTI model and aerosolized variants showing activity across pulmonary infection models.Oct 7, 2026
- Lakewood-Amedex reported promising MIC data for Nu-3 against contemporary clinical isolates from infected diabetic foot ulcers, showing consistent bactericidal activity across resistance profiles.Sep 29, 2026
- Lakewood-Amedex secured central and local IRB approvals and confirmed site readiness to initiate its Phase 2a study of Nu-3 topical gel in mildly infected diabetic foot ulcers.Sep 21, 2026
- Lakewood Amedex received USPTO patent allowance for antimicrobial compoundsSep 1, 2026
- Lakewood Amedex received U.S. patent allowance for its antimicrobial platformSep 1, 2026
FDA designations
Nothing here yet
News
- Lakewood-Amedex Biotherapeutics reports positive activity against recent clinical isolates from infected diabetic foot ulcersSep 28, 2026
- Lakewood-Amedex Biotherapeutics doses the first patient in a Phase 2a trial of Nu-3 for infected diabetic foot ulcersSep 24, 2026
- Lakewood-Amedex received IRB approval and confirmed clinical site readiness to begin the Phase 2a trial of Nu-3 for infected diabetic foot ulcersSep 18, 2026